In a significant advancement for the poultry industry, scientists at the renowned Pirbright Institute in Surrey have unveiled a novel approach to vaccine design, targeting the highly contagious Infectious Bronchitis Virus (IBV), also known as avian coronavirus.
This respiratory disease poses serious threats to both the health and productivity of chickens, leading to symptoms such as snicking, wheezing, watery eyes, and nasal discharge.
Beyond animal welfare concerns, IBV infections result in reduced weight gain and a notable decline in egg production, impacting the poultry sector’s economic viability. Traditionally, control measures have relied on a combination of live attenuated and inactivated vaccines. The former involves weakening the virus by repeatedly cultivating it in eggs until it loses its virulence.
However, experts at Pirbright have raised concerns about this conventional method’s unpredictability, as it depends on random genetic mutations that can sometimes compromise vaccine efficacy. Moreover, the process is time-consuming, rendering it less effective in responding swiftly to emerging IBV strains.
In response, the Pirbright team has embarked on an innovative ‘targeted attenuation’ strategy. This method entails making precise modifications to weaken the virus without diminishing its capacity to stimulate immunity. Notably, while vaccines against other coronaviruses, such as SARS-CoV-2, primarily target the Spike (S) protein, this approach has proven ineffective for IBV, underscoring the necessity for alternative strategies.
The implications of this research are profound. The targeted attenuation technique promises to alleviate the burden of IBV on the poultry sector, enhance animal welfare, and bolster food security. Dr. Erica Bickerton, lead of the Coronavirus group at Pirbright, emphasised the potential of this approach, stating, “By using targeted attenuation we can develop vaccines that are more effective and adaptable to new strains. It also opens up the possibility of developing vaccines against other coronaviruses.”
This breakthrough signifies a pivotal moment in veterinary science, offering hope for more efficient and adaptable vaccines to safeguard the poultry industry against IBV and potentially other coronavirus-related threats in the future.
